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Abstract
Background: Urinary kidney injury molecule 1 is a recently discovered early biomarker for renal damage that has
been proven to be correlated to urinary cadmium in rats. However, so far the association between urinary
cadmium and kidney injury molecule 1 in humans after long-term, low-dose cadmium exposure has not been
studied.
Methods: We collected urine and blood samples from 153 non-smoking men and women aged 60+, living in an
area with moderate cadmium pollution from a non-ferrous metal plant for a significant period. Urinary cadmium
and urinary kidney injury molecule 1 as well as other renal biomarkers (alpha1-microglobulin, beta2-microglobulin,
blood urea nitrogen, urinary proteins and microalbumin) were assessed.
Results: Both before (r = 0.20; p = 0.01) and after (partial r = 0.32; p < 0.0001) adjustment for creatinine, age, sex,
past smoking, socio-economic status and body mass index, urinary kidney injury molecule 1 correlated with urinary
cadmium concentrations. No significant association was found between the other studied renal biomarkers and
urinary cadmium.
Conclusions: We showed that urinary kidney injury molecule 1 levels are positively correlated with urinary
cadmium concentration in an elderly population after long-term, low-dose exposure to cadmium, while other
classical markers do not show an association. Therefore, urinary kidney injury molecule 1 might be considered as a
biomarker for early-stage metal-induced kidney injury by cadmium.
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Background
Cadmium (Cd) is an ever-present and global environ-
mental pollutant [1]. Current Cd emission has been
drastically reduced, but Cd continues to be a health
hazard, because historically accumulated Cd cannot be
degraded and its half-life in the body is long (10-30
years) [2]. Next to the bone [3], a main target for
chronic, low-level Cd exposure is the kidney, leading to
proximal tubule dysfunction [2,4,5]. Tubular dysfunction
causes polyuria and low molecular weight proteinuria
and some of these urinary proteins, e.g. a-1 microglobu-
lin (a1M-U)[6], b-2 microglobulin (b2M-U)[7,8] and
clara cell protein-16 (CC-16-U)[9] are used as urinary
biomarkers of the early stages of Cd nephrotoxicity. In
other studies, Cd toxicity is monitored by the Cd-bind-
ing protein metallothionein in urine [8,10,11], N-acetyl-
beta-glucosaminidase (NAG) [7,8] or even urinary Cd
itself [7,11-13]. Although these renal biomarkers are
widely used, questions arose concerning specificity and
sensitivity [6,9,11,14-17]. There clearly is a need for an
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caused by Cd.
Kidney injury molecule 1 (KIM-1), originally discov-
ered by Ichimura et al., is a type 1 membrane glycopro-
tein found on renal proximal tubule epithelial cells. It
contains in its extracellular portion a unique 6-cysteine
immunoglobulin-like domain and a mucin-domain [18].
An intracellular highly conserved tyrosine kinase phos-
phorylation motif is a strong indicator that KIM-1 is a
cell signaling molecule [19].
KIM-1 expression is induced in a variety of renal dis-
eases, whereas in healthy kidney tissue KIM-1 is vir-
tually undetectable [18,20]. In the case of kidney
damage, KIM-1 is expressed on the apical membrane
followed by cleavage of the ectodomain (90 kDa) which
is released in the urine in rodents [18,19,21-24] and in
humans [25-28]. KIM-1 is upregulated in the proximal
tubule during dedifferentiation of the kidney epithelium,
an early manifestation in response to damage [29].
In rats, Prozialeck et al. showed that KIM-1 is a very
early urinary marker for Cd-induced kidney injury [23].
They showed that KIM-1 was elevated before other
urinary biomarkers of Cd nephrotoxicity, such as metal-
lothionein, CC-16-U, proteinuria, a-glutathione-S-trans-
ferase (a-GST), NAG and Cd itself [23,30]. Moreover
they showed that the Cd-induced increase in KIM-1
expression can be detected before signs of necrosis
appear and when there is only a modest level of apopto-
sis in the proximal tubule [29].
It has been well established in humans that KIM-1
appears in the urine at an early stage in kidney damage
and also, that Cd affects proximal tubule function when
the Cd burden is high. Cd triggers the expression of
KIM-1 at a very early stage in animal models [31]. The
aim of the present pilot study is to assess the appear-
ance of urinary KIM-1 after long-term, low-dose Cd
exposure in humans, because, to our knowledge, this
has not been investigated in the population.
Methods
Study population and sample collection
The total population (n = 3069) of the general practice
in Genk is registered in the framework of a registration
network for family practices in Flanders (INTEGO) [32].
The study area is representative of the total population.
Non-smoking men and women, 60 to 80 years old, with
no acute infection at enrolment and no history of
malignancies, were selected in the southern region of
Genk from a quarter adjacent to an industrial area
where a non-ferrous metal plant, a major motor com-
pany and a power station are located and which is
crossed by multiple highroads. Sampling was combined
with the annual influenza vaccination at a local doctor’s
practice. Eligible people were notified in advance by
letter. Of those that routinely are advised for influenza
vaccination, approximately 86% joined the vaccination
program. Of those that were eligible, 154 were
recruited, and 99% agreed to participate in our study.
Of the 153 persons that agreed to participate (79
women; mean age 71 yr and 74 men; mean age 70 yr),
for one person no urinary sample was collected and this
person was not included in the analyses. Personal infor-
mation was processed anonymously in conformity with
privacy policy. Informed consent was obtained from all
participants and the study was approved by the ethics
committee of the Ziekenhuis Oost-Limburg (ZOL), Bel-
gium. Questionnaires were administered to assess life-
style, profession, education, past smoking status, as well
as data on age, weight and gender. Family income was
given as net monthly overall family income and subdi-
vided into low (<1500€), medium (1500€ - 3000€)a n d
high (>3000€) family income. Education was coded as
low (primary school), medium (high school) and high
(university). Past smoking was quantified as pack years
by multiplying the number of packs of cigarettes
smoked per day by the number of years the person has
smoked. Finally, individual medical backgrounds were
used to determine possible interference of drug admin-
istration or diseases, with kidney function. Second
morning urine samples and blood samples were col-
lected from all participants. Samples were aliquoted (6
× 2 ml), stored on ice for a maximum of four hours
and subsequently frozen at -80°C.
Routine analyses and renal biomarker measurements
Routine analyses of the urine samples were performed in
the clinical laboratory of the regional hospital ZOL in
Genk. Using an automated analyzer (Modular
® P800-
ISE900 System, Roche Diagnostics; Mannheim, Ger-
many), the following urinary analyses were performed,
according to manufacturer’s instructions: creatinine
according to the kinetic Jaffe method (compensated, rate
blanked), total protein by a colorimetric biuret test and
a1M-U based on immunological agglutination. b2M-U
was determined by particle-enhanced immunonephelo-
metry using the BN ProSpec (Siemens Healthcare Diag-
nostics; Marburg, Germany). Microalbumin was
nephelometrically determined (Immage
® Immunochem-
istry System, Beckman Coulter; Suarlee, Belgium). Blood
urea and serum creatinine were measured following the
same assays as with the urinary analyses. BUN (blood
urea nitrogen) was determined as blood urea times two
(covering the molar mass of the two nitrogens). Urinary
KIM-1 was analyzed by a commercially available sand-
wich ELISA: Human TIM-1/KIM-1/HAVCR Duoset
(R&D Systems; Abingdon, U.K.), validated by Chaturvedi
et al. [33]. The assay procedure was performed accord-
ing to the prescriptions of the manufacturer. When
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surement [34]. The optical density was determined with
a fluorescence microplate reader (FLUOstar OPTIMA,
BMG Labtechnologies; Offenburg, Germany), set to 450
nm with a wavelength correction at 540 nm. All samples
were measured in duplicate.
Urinary Cd analyses
Cd concentrations in urine were analyzed by means of
inductively coupled plasma mass spectrometry (ICP-MS)
using the ELAN
® DRC-e (Axial Field™ Technology,
Perkin Elmer SCIEX; Zaventem, Belgium). Urine sam-
ples and standards were diluted 1:10 in 1% nitric acid.
Statistical analyses
For database management and statistical analyses, SAS
Software version 9.1 (version 9.1, SAS Institute Inc,
Cary (NC), USA) and GraphPad Prism 5.01 (GraphPad
Software Inc, La Jolla (CA), USA) were used. Non-nor-
mally distributed data were log transformed. For com-
parison of means and proportions, we applied Student’s
t-test and the c
2-statistic, respectively. We investigated
associations between markers of kidney function and
urinary cadmium using Pearson’s correlation and multi-
ple linear regression. Estimated effect sizes and 95% CI
were calculated from linear regression coefficients for a
two-fold increase in urinary Cd. A priori three models
were chosen: model 1 shows unadjusted data, in model
2, results are adjusted for creatinine, sex, age, past
smoking, body mass index (BMI) and socio-economic
status (SES; based on educational degree and monthly
family income), while in model 3 data are adjusted for
sex, age, past smoking, BMI and SES and given as func-
tion of creatinine. When residuals are calculated (fig-
ures), we adjusted the different parameters for
creatinine, sex, age, past smoking, BMI and SES, in
order to remove these potential confounding factors
from the association. Correlations were considered sig-
nificant when p < 0.05. All tests were two-sided.
Results
The study population consists of 153 participants (52%
women) with a mean age of 71 years. Patient character-
istics can be found in table 1. From all the participants,
of the 54% that have ever smoked there was a significant
difference between men and women (75% and 35%
respectively, p < 0.0001). Those who had smoked in the
past had an average of 18 pack years. The average dis-
tance between their residence and the heavy metal
industrial zone was 2743 m, while the mean distance to
the two main roads was 294 m and 562 m. Participants
have lived at their current addresses for a mean period
of 36 years (range: 3 to 75 years). Geometric mean urin-
ary Cd level was 0.76 μg/g creatinine. Geometric mean
of the urinary KIM-1 concentrations as well as the
mean concentrations of other renal biomarkers (b2M-U,
a1 M - U ,B U N ,u r i n a r yp r o t e i n s ,m i c r o a l b u m i n u r i a )a n d
creatinine are given in table 2.
Urinary KIM-1 was not influenced by gender (p =
0.83), age (p = 0.08), distance between housing and
Table 1 Participants characteristics
Characteristics Total group
(n = 153)
Anthropometrics
Sex, female 79 (52%)
Age, years 71 ± 4.5
BMI, kg/m
2 27.2 ± 4.3
Socio-economic status*°
Low 62 (41%)
Median 59 (39%)
High 29 (19%)
Familial income, per month°
<1500€ 71 (47%)
1500-3000€ 77 (51%)
>3000€ 2 (1%)
Smoking status
Ex-smoker
† 81 (54%)
Never smoked
† 68 (46%)
Exposure to environmental tobacco smoke
¶ 61 (48%)
Use of medication
§
Antiplatelet medication 13 (9%)
Statins 81 (53%)
ACE inhibitor 27 (18%)
Insulin 5 (3%)
Antidiabetic medication 19 (13%)
NSAID 23 (15%)
Blood analyses
Hemoglobin, g/dl 14.17 ± 1.24
Red blood cells, 10
6/μl
“ 4.75 (4.68 - 4.82)
White blood cells, 10
3/μl
“ 6.58 (5.76 - 7.53)
Neutrophils, %
“ 55.10 (53.60 - 56.66)
Lymphocytes, %
“ 29.70 (28.35 - 31.12)
Monocytes, %
“ 6.52 (5.76 - 7.53)
Eosinophils, %
“ 2.79 (2.39 - 3.25)
Ferritin, ng/ml
“ 121.9 (108.0 - 137.6)
CRP, mg/dl
Creatinine, mg/dl
“ 0.86 (0.83 - 0.89)
Glucose, mg/dl
“ 99.95 (96.50 - 103.50)
Cholesterol, mg/dl 200.7 ± 37.26
HDL, mg/dl
“ 56.64 (54.04 - 59.37)
LDL, mg/dl 114.4 ± 34.48
Triglycerides, mg/dl
“ 122.1 (112.8 - 132.1)
Data are arithmetic mean ± standard deviation or absolute number
(percentage of study population);
“ data which are not normally distributed and for which geometric mean (95%
confidence interval) is given.
*Based on educational degree; °n = 150;
†n = 149;
§n = 152;
¶ n = 126
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(p = 0.14) and BMI (p = 0.83). Both before (table 3 and
Figure 1) and after adjustment (table 3) for sex, age,
past smoking, BMI and socio-economic status (including
education and income) variables, KIM-1 correlated posi-
tively and significantly with the urinary cadmium con-
centration. For the other biomarkers (BUN,
microalbuminuria and urinary proteins) unadjusted and
adjusted multiple linear regression models showed no
significant correlation between these biomarkers of kid-
n e yf u n c t i o na n du r i n a r yC d( s e eF i g u r e1a n dt a b l e3 ) .
Both for b2M-U and a1M-U a considerable amount of
urine samples that were tested (84% and 28% respec-
tively) were below the limit of detection, suggesting the
assessments that were used were not sensitive enough.
Therefore, no analysis was conducted for b2M-U and
a1M-U in association with Cd.
Discussion
About a decade ago, KIM-1 was discovered in the
search for molecules involved in the pathogenesis of
acute kidney injury. We demonstrated among elderly a
robust association between urinary KIM-1 and urinary
Cd. Depending on the biomarker of nephrotoxicity
thresholds of urinary Cd can range from about 2.4 μg
Cd/g creatinine for the onset of early biochemical altera-
tions (e.g. hypercalciuria) to 10 μg Cd/g creatinine for
the development of the classic tubular microproteinuria
[13]. Here, we showed biochemical changes at urinary
Cd levels below 1 μg Cd/g creatinine.
Ichimura et al. were the first to describe KIM-1 as a
type 1 membrane glycoprotein, which contains a 6-
cystein immunoglobulin-like domain in its extracellular
portion, and a Thr/Ser-Pro rich domain characteristic of
mucin-like O-glycosylated proteins [18]. KIM-1 also has
a transmembrane domain and a cytoplasmic domain,
which contains a conservative tyrosine kinase phosphor-
ylation site, indicating that KIM-1 may be a signaling
molecule [19]. In healthy kidney tissue, KIM-1 is vir-
tually undetectable whereas in the injured kidney, KIM-
1 expression is rapidly upreg u l a t e da tt h ea p i c a ls i d eo f
the proximal tubule [18,21]. This process is
Table 2 Mean urinary cadmium and renal biomarker
values
Mean (95% CI)
Cadmium, μg/l† 0.80 (0.73 - 0.88)
Cadmium/creatinine, μg/g creat† 0.76 (0.70 - 0.84)
KIM-1, pg/ml* 569 (498 - 651)
KIM-1/creatinine, μg/g creat* 0.55 (0.49 - 0.62)
a1-microglobulin, mg/l† 3.19 (2.58 - 3.91)
a1-microglobulin/creatinine, mg/g creat† 2.97 (2.42 - 3.64)
Proteins, mg/l* 71.80 (63.81 - 80.80)
Proteins/creatinine, mg/g creat* 66.61 (59.99 - 73.95)
Albumin, mg/dl* 8.73 (7.46 - 10.21)
Albumin/creatinine, mg/g creat* 8.43 (7.32 - 9.70)
b2-microglobulin, mg/l‡ 0.12 (0.11 - 0.13)
b2-microglobulin/creatinine, mg/g creat‡ 0.12 (0.11 - 0.13)
BUN, mg/dl† 35.94 (34.47 - 37.46)
Urinary creatinine, mg/dl* 104.9 (96.55 - 114.0)
Geometric mean (95% confidence interval) of urinary cadmium and renal
biomarkers. All parameters were measured in urine; except for blood urea
nitrogen, which was measured in blood. † n = 152; * n = 153; ‡ n = 140.
Table 3 Estimated change (%) in urinary biomarker levels
calculated for a two-fold increase in urinary cadmium
concentration
Estimated effect size
(%)
95%CI(%) R
2 p-
value
Model 1
KIM-1 23.73 6.92 to
43.18
0.05 0.005
Microalbumin 4.40 -13.42 to
25.89
0.001 0.65
Proteins 5.66 -3.52 to
15.71
0.01 0.24
BUN -5.65 -10.53 to
-0.49
0.04 0.03
Model 2
KIM-1 39.54 18.26 to
64.65
0.27 0.0001
Microalbumin 4.85 -14.14 to
28.03
0.27 0.64
Proteins 3.15 -6.26 to
13.52
0.49 0.53
BUN -4.66 -9.83 to
0.80
0.08 0.10
Model 3
KIM-1 26.59 7.82 to
48.62
0.13 0.005
Microalbumin -2.80 -20.42 to
18.78
0.09 0.78
Proteins 0.66 -8.65 to
10.92
0.11 0.89
BUN -3.69 -8.99 to
1.91
0.07 0.19
All data were log-transformed and estimated effect size is given as %
estimated effect size calculated for a two-fold increase in urinary cadmium
concentrations (μg/g creatinine) with the corresponding 95% confidence
interval, R
2 gives the explained variance.
Abbreviations: KIM-1, kidney injury molecule 1; BUN, blood urea nitrogen; CI,
confidence interval
Model 1: unadjusted but given as function of creatinine
Model 2: adjusted for creatinine (except for blood urea nitrogen), sex, age,
past smoking, body mass index and socio-economic status
Model 3: adjusted for sex, age, past smoking, body mass index and socio-
economic status; given as a function of creatinine.
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domain of KIM-1 into the urine [19]. The ectodomain is
stable in urine [34] and has shown to be a sensitive bio-
marker of renal injury induced by a variety of agents
including the heavy metal Cd: Prozialeck et al. have pro-
ven KIM-1 to be a putative early biomarker for proximal
tubule damage caused by high doses of Cd in rats, out-
performing the classic biomarkers such as metallothio-
nein, CC-16, a-GST and urinary proteins [23,29,30]. In
addition, KIM-1 appears before any lethal injury is
detected in the proximal tubule epithelial cells [29].
Thus, using this biomarker, very early detection of cell
stress may be possible, which would allow for the rever-
sal and/or the treatment of Cd-induced kidney injury
[35]. To our knowledge however, no research has ever
focused on the correlation of the Cd burden and the
urinary KIM-1 concentrations in humans.
S i n c ew ew e r em a i n l yi n t e r e s t e di nt h ep o s s i b l er o l e
for KIM-1 as a biomarker after long term environmental
Cd intoxication, we chose a non-smoking elderly popu-
lation living near a non-ferrous metal industrial zone in
Genk for a longer period. In this region, levels of Cd
have been reported to be higher than in other Belgian
gauging regions according to the Flemish environmental
agency (VMM: Mira-T indicator rapport 2008).
Both blood and urinary Cd are indicators of Cd body
burden; however urinary Cd correlates better with the
duration of exposure than does blood Cd [12,36,37],
which makes it a better indicator for long-term Cd
exposure. Therefore, we compared the urinary Cd
A) B)
C) D)
R=0.32
p<0.0001
R= 0.14
P=0.09
R= 0.04
P=0.63
R=0.06
P=0.52
Figure 1 Correlations of the residuals of urinary KIM-1 and the other biomarkers with the residuals of urinary cadmium. Correlations of
the residuals of A) log KIM-1, B) log blood urea nitrogen, C) log albumin and D) log proteins with the residuals of log cadmium. All parameters
were measured in urine, except for blood urea nitrogen. Residuals were computed to remove the variance by age, sex, socio-economic status,
body mass index, creatinine (except for blood urea nitrogen) and past smoking. Data on KIM-1, cadmium, protein, blood urea nitrogen and
albumin concentrations were log-transformed to obtain a normal distribution. Abbreviations:KIM-1: kidney injury molecule 1; BUN, blood urea
nitrogen.
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nephrotoxicity.
As shown in Figure 1, after adjustment for creatinine,
sex, age, past smoking, BMI and SES, only KIM-1 was
significantly correlated with Cd levels.
Urinary Cd concentration averaged below 1 μg/g crea-
tinine among our population. This may explain why
albuminuria, proteinuria and BUN did not correlate
with urinary Cd. These markers mainly identify later
stages of Cd-induced kidney injury [38,39].
Although a1M-U is stable across physiological pH [40],
its specificity is undermined by the influence of several
conditions such as liver disease [15], HIV [16], mood dis-
orders [17] and other environmental influences, for exam-
p l el e a de x p o s u r e[ 4 1 ] .I nc o n t r a s tt ob2M-U, which is
degraded rapidly in acidic urine [42], urinary KIM-1 has
been proven to be stable over the physiological range of
urinary pH values [34]. Moreover, it originates from proxi-
mal tubule cells [20,43], which makes it a much more spe-
cific renal biomarker than proteins originating from other
parts of the body. Prozialeck et al. found in rats that urin-
ary KIM-1 starts to increase significantly earlier and at
lower doses of Cd than metallothionein, CC-16, proteins
and a-GST [29,30,44]. The present study corroborates this
high sensitivity for human subjects.
Since KIM-1 has a high cysteine content and Cd is
known for its high binding capacity with cystein com-
plexes [45], future research should focus on whether
this influences the correlation between urinary KIM-1
and urinary Cd.
Conclusions
In conclusion, this pilot study shows that urinary KIM-1
levels are significantly correlated with urinary Cd levels
in an elderly population after long-term, low-dose expo-
sure to Cd, probably indicating beginning metal-induced
kidney injury. To further elucidate the exact role KIM-1
can play as a biomarker for early cadmium-induced
renal damage, future research should concentrate on the
comparison of KIM-1 with other biomarkers by using
the most sensitive and reliable measuring techniques,
with inclusion of a paired control group, living in unpol-
luted areas.
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